I completed my PhD in Cancer Biology at MD Anderson Cancer Center, Houston, TX, and started my journey at J&J R&D, where I helped understand the mechanism of action for a currently approved bispecific antibody, Rybrevant. Since then, I have led multiple novel drug discovery programs through the pre-clinical phase, most notably, a T-cell redirecting bispecific antibody (ENPP3xCD3) that recently began Phase I clinical trials for multiple solid tumors. I currently lead the Lung Cancer Discovery team working on developing novel antibody-based therapeutics to treat solid tumors by leveraging several modalities including antibody-drug conjugates, T-cell redirection, and CAR-T. I hope to continue to make a difference in the lives of cancer patients by developing novel and innovative drugs and treatments and mentor and train younger scientists along the way. Outside work, I love to travel, explore new countries, and experience the local culture and food.